thalidomide has been researched along with Angiomatosis Retinae in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Complications from hemangioblastoma are among the principal causes of death from this syndrome." | 5.35 | Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel-Lindau disease. ( Aricò, M; Buccoliero, AM; Genitori, L; Giordano, F; Mussa, F; Sanzo, M; Sardi, I, 2009) |
| "Complications from hemangioblastoma are among the principal causes of death from this syndrome." | 1.35 | Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel-Lindau disease. ( Aricò, M; Buccoliero, AM; Genitori, L; Giordano, F; Mussa, F; Sanzo, M; Sardi, I, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaelin, WG | 1 |
| Salim, DK | 1 |
| Sardi, I | 1 |
| Sanzo, M | 1 |
| Giordano, F | 1 |
| Buccoliero, AM | 1 |
| Mussa, F | 1 |
| Aricò, M | 1 |
| Genitori, L | 1 |
| Tan, DS | 1 |
| Evanson, J | 1 |
| Plowman, PN | 1 |
| Chew, SL | 1 |
4 other studies available for thalidomide and Angiomatosis Retinae
| Article | Year |
|---|---|
THE JEREMIAH METZGER LECTURE:VON HIPPEL-LINDAU DISEASE: INSIGHTS INTO OXYGEN SENSING, CANCER AND DRUGGING THE UNDRUGGABLE.
Topics: Carcinoma, Renal Cell; Humans; Hypoxia; Kidney Neoplasms; Ligases; Oxygen; Prolyl Hydroxylases; Thal | 2022 |
Continuous angiogenesis inhibition in the treatment for von Hippel-Lindau-related hemangioblastomas of retina and spinal cord.
Topics: Angiogenesis Inhibitors; Hemangioblastoma; Humans; Male; Retina; Spinal Cord; Thalidomide; Vascular | 2019 |
Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel-Lindau disease.
Topics: Angiogenesis Inhibitors; Child; Female; Hemangioblastoma; Humans; Spinal Cord Neoplasms; Thalidomide | 2009 |
Post-radiation inflammatory reaction controlled with thalidomide and rofecoxib.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Brain Edema; Brain Neoplasms; Female; Hemangioblasto | 2004 |